Despite numerous major changes looming in the healthcare industry, the 2015 edition of the Great American Physician Survey found that U.S. physicians are still happy in their careers.

Navidea Biopharmaceuticals Inc. received initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH). The grant will be used to fund preclinical studies examining the safety of intravenous (IV) injection of Tc99m tilmanocept, a Manocept platform product.

Results of the PLATFORM trial indicate fractional flow reserve computed tomography (FFR-CT) can obviate the need for invasive tests in up to 61 percent of patients with chest pain and suspected coronary artery disease. The results were presented at the European Society of Cardiology (ESC) Congress 2015.

Significant national and international momentum is building to include a proton therapy unit as part of the planned expansion of SAHMRI, South Australia’s Health and Medical Research Institute. It would be the first facility in the Southern Hemisphere to deliver proton therapy.

Men with relatively unaggressive prostate tumors whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to a study from the Brady Urological Institute at Johns Hopkins.